Hier beginnt der Kopfbereich - Meta-Navigation und Logos

Kein Link zur Sprachversion EN EN

Hier beginnt die Unternavigation für den Bereich

Ihr Ausdruck wurde in der folgenden Navigationsebene erstellt:

Hier beginnt der Inhaltsbereich
Herzlich willkommen im Portal für unsere Kollegen und Partner in der Medizin!
Visual Content 1
Visual Content 2

Arbeitsgruppe Massinga Loembe



Dr Marguerite Massinga Loembe heads CERMEL research laboratory and coordinates group efforts dedicated to laboratory systems reinforcement for better infectious diseases control locally, but also in neighbouring Sub-Saharan African countries, focusing on :

Quality ensured laboratory services for clinical trials and research:

-Establishing GCLP and ISO 15189 compliant laboratory processes and assays, alongside the SLIPTA framework (WHO stepwise lab improvement process towards accreditation), for immunology endpoints assessment in support to ongoing clinical and vaccine trials.

-Setting up quality ensured specimen repositories for development and validation of new molecular and immunological diagnostic tools.

Health systems reinforcement and programmatic support:

-Providing technical assistance to high-disease burden countries to improve the efficiency of health care delivery systems, with special focus on laboratories.

-Fostering linkage between researchers, policy makers and national health authorities to ensure better uptake of new recommendations, technologies and scale up new diagnostics.

In Gabon, this work is exemplified by the country level support provided to the National TB Control Program for TB laboratory network strategic planning and implementation as well as programmatic management of drug resistant TB (diagnostic and care as part of Global Fund TB grant.




Marguerite Massinga Loembe, Dr
Hopital Albert Schweitzer, B.P.118, Lambaréné, Gabon





Relevante Publikationen/Relevant publications


Added Value of Long-Term Cytokine Release Assays to Detect Mycobacterium tuberculosis Infection in HIV-Infected Subjects in Uganda.

Dirix V, Schepers K, Massinga-Loembe M, Worodria W, Colebunders R, Singh M, Locht C, Kestens L, Mascart F; TB-IRIS study group.

J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):344-52


Enhanced laboratory capacity development: a boost for effective tuberculosis control in resource-limited settings.

Alabi AS, Traoré AN, Loembe MM, Ateba-Ngoa U, Frank M, Adegnika AA, Lell B, Mahoumbou J, Köhler C, Kremsner PG, Grobusch MP; CERMEL TB CapDev Group..

Int J Infect Dis. 2016 Nov 22. pii: S1201-9712(16)31622-8.


Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.

Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaître B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmüller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA.

N Engl J Med. 2016 Apr 28;374(17):1647-60


Urinary lipoarabinomannan as predictor for the tuberculosis immune reconstitution inflammatory syndrome.

Conesa-Botella A, Loembé MM, Manabe YC, Worodria W, Mazakpwe D, Luzinda K, Mayanja-Kizza H, Miri M, Mbabazi O, Koole O, Kestens L, Colebunders R; TB IRIS Group..

J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):463-8




Link zu unserer Partnerinstitution:






Hier beginnt die Marginalspalte Suche und verschieden Module

Hier beginnt die Fusszeile - Impressum und Datenschutz